Sage Therapeutics (NASDAQ:SAGE) Lowered to “Sell” Rating by StockNews.com

StockNews.com cut shares of Sage Therapeutics (NASDAQ:SAGE) from a hold rating to a sell rating in a report issued on Thursday.

Several other equities research analysts also recently weighed in on SAGE. Needham & Company LLC reaffirmed a “hold” rating on shares of Sage Therapeutics in a report on Wednesday. Mizuho lowered their target price on shares of Sage Therapeutics from $18.00 to $16.00 and set a “neutral” rating on the stock in a report on Friday, July 19th. Truist Financial cut their price target on shares of Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating for the company in a report on Wednesday. The Goldman Sachs Group lowered their price objective on Sage Therapeutics from $19.00 to $11.00 and set a “neutral” rating on the stock in a report on Friday, July 26th. Finally, Robert W. Baird reduced their price target on Sage Therapeutics from $13.00 to $9.00 and set a “neutral” rating for the company in a report on Wednesday, October 9th. Three research analysts have rated the stock with a sell rating, seventeen have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, Sage Therapeutics has a consensus rating of “Hold” and a consensus price target of $12.89.

Sage Therapeutics Stock Down 1.5 %

SAGE traded down $0.09 during trading on Thursday, hitting $5.99. 22,854 shares of the stock were exchanged, compared to its average volume of 975,193. Sage Therapeutics has a 1-year low of $5.84 and a 1-year high of $28.26. The stock has a fifty day moving average price of $7.44 and a two-hundred day moving average price of $9.95. The firm has a market capitalization of $366.43 million, a P/E ratio of -1.09 and a beta of 0.91.

Sage Therapeutics (NASDAQ:SAGE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.52) by ($0.01). Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. The business had revenue of $11.87 million for the quarter, compared to analysts’ expectations of $10.80 million. During the same quarter last year, the business posted ($2.81) earnings per share. The business’s revenue was up 337.1% on a year-over-year basis. Analysts predict that Sage Therapeutics will post -6.43 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of SAGE. ProShare Advisors LLC lifted its holdings in Sage Therapeutics by 9.0% in the 1st quarter. ProShare Advisors LLC now owns 13,713 shares of the biopharmaceutical company’s stock valued at $257,000 after purchasing an additional 1,130 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its position in Sage Therapeutics by 9.8% during the first quarter. State Board of Administration of Florida Retirement System now owns 16,644 shares of the biopharmaceutical company’s stock worth $312,000 after acquiring an additional 1,480 shares during the last quarter. Quest Partners LLC grew its stake in Sage Therapeutics by 14.5% in the 2nd quarter. Quest Partners LLC now owns 11,763 shares of the biopharmaceutical company’s stock worth $128,000 after acquiring an additional 1,486 shares during the period. Inspire Investing LLC raised its holdings in Sage Therapeutics by 9.4% in the 1st quarter. Inspire Investing LLC now owns 19,234 shares of the biopharmaceutical company’s stock valued at $360,000 after acquiring an additional 1,652 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Sage Therapeutics by 4.6% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 38,568 shares of the biopharmaceutical company’s stock worth $723,000 after purchasing an additional 1,693 shares during the period. 99.22% of the stock is currently owned by institutional investors and hedge funds.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.